Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioplasty

Journal of Pathology

Volumn 180, Issue 3, 1996, Pages 311-316

  Matsuura, Ritsuko ^a   Isaka, Naoki ^a,b   Imanaka Yoshida, Kyoko ^b   Yoshida, Toshimichi ^b   Sakakura, Teruyo ^b   Nakano, Takeshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY   (Japan)

Author keywords

Cell proliferation; Coronary artery; Human; Proteoglycan; PTCA; Restenosis

Indexed keywords

ACTIN; MONOCLONAL ANTIBODY KI 67; VERSICAN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATHERECTOMY; CELL COUNT; CELL DIVISION; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LECTINS, C-TYPE; MALE; MIDDLE AGED; PROTEOCHONDROITIN SULFATES; RECURRENCE; TIME FACTORS; VERSICANS;

EID: 0029807702     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199611)180:3<311::AID-PATH657>3.0.CO;2-B     Document Type: Article

References (29)

1. Jackson CL. Animal models of restenosis. Trends Cardiovasc Med 1994; 4: 122-130.
2. Pickering JG, Weir L, Jekanowski J, et al. Proliferative activity in peripheral and coronary atherosclerotic plaque among patients undergoing percutaneous revasculamation. J Clin Invest 1993; 91: 1469-1480.
3. O'Brien ER, Alpers CE, Stewart DK, et al. Proliferation in primary and restenotic coronary atherectomy tissue implications for antiproliferative therapy. Circ Res 1993; 73: 223-231.
4. Strauss BH, Umans VA, Suylen RJ. et al. Directional atherectomy for treatment of restenosis within coronary stents clinical, angiographic and histologic results. J Am Coll Cardiol 1992; 20: 1465-1473.
5. The multicenter European research trial with Cilazapril after angioplasty to prevent transluminal coronary obstruction and restenosis (MERCATOR) study group. Does the new angiotensin converting enzyme inhibitor Cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study; a multicenter. randomized, double-blind placebo-controlled trial. Circulation 1992; 86: 100 110.
6. Franklin SM, Faxon DP. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery Disease 1993; 4: 232-242.
7. Ellis SG, Roubin GS, Wilentz J. et al. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989; 117: 777-782.
8. Whitworth HB, Roubin GS, Hollman J, et al. Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1986; 8: 1271-1276.
9. Popma JJ, Califf RM, Topol ET. Clinical trials of restenosis after coronary angioplasty. Circulation 1991; 84: 1426-1436.
10. Wight TN, Heinegard DK, Hascall VC. Proteoglyeans. Structure and function. In: Hay ED, ed. Cell Biology of Extracellular Matrix. 2nd edn. New York: Plenum Press. 1991; 45-77.
11. Shin RW, Iwaki T, Kitamoto T, et al. Methods in laboratory investigation; hydrated autoclave pretreatment enhances TAU immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues, Lab Invest 1991; 64: 693-702.
12. Sobue M, Nakashima N, Fukatsu T, et al. Production and immunohistochemical characterization of a monoclonal antibody raised to proteoglycan purified from a human yolk sac tumor. Histochem J 1989; 21: 455-460.
13. Nobuyoshi M, Kimura T, Ohishi H, et al. Restenosis after percutaneous transluminal coronary angioplasty: pathologic observations in 20 patients. J Am Coll Cardiol 1991; 17: 433-439.
14. Ueda M, Becker AE, Tsukada T, et al. Fibrocellular response after percutaneous transluminal coronary angioplasty: an immunocytochemical analysis of the cellular composition. Circulation 1991; 83: 1327-1332.
15. Clowes AW, Reidy MA. Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983; 49: 327-333.
16. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985; 57: 105-112.
17. Nobuyoshi M, Kimura T. Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988; 12: 616-623.
18. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. Circulation 1988; 77: 361-371.
19. Clowes AM, Reidy MA, Clowes MM. Mechanism of stenosis after arterial injury. Lab Invest 1983; 49: 208-215.
20. Strauss BH, Chisholm RJ, Keeley FW, et al. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ Res 1994; 75: 650-658.
21. MacLeod DC, Strauss BH. Jong M, et al. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol 1994; 23: 59-65.
22. Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992; 20: 1264-1293.
23. Nikkari ST, Jarvelainen HT, Wight TN, et al. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol 1994; 144: 1348-1356.
24. Clowes AW, Clowes MM, Gown AM, et al. Localization of proteoheparan sulfate in rat aorta. Histochemistry 1984; 80: 379-384.
25. Volker W, Schmidt A, Oortmann W, et al. Mapping of proteoglycans in atherosclerotic lesions. Eur Heart J 1990; 11: 29-40.
26. Sumuvuori H, Karkola K, Mottonen M, et al. Glycosaminoglycans in normal and atherosclerotic human coronary arteries. Lab Invest 1986; 54: 402-407.
27. Alavi MZ, Moore S. Proteoglycan composition of rabbit arterial wall under conditions of experimentally induced atherosclerosis. Atherosclerosis 1987; 63: 65-74.
28. Riessen R, Isner JM, Blessing E, et al. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol 1994; 144: 962-974.
29. Wolf YG, Rasmussen LM, Ruoslahti E. Antibodies against transforming growth factor-beta I suppress intimal hyperplasia in a rat model. J Clin Invest 1994; 93: 1172-1178.